Day Two Thursday 1 March 2012

Day One Wednesday 29 February 2012 ›

Day Two Thursday 1 March 2012 ›

last modified: 07 March '12

Please enable javascript to see more information on speakers

8.30am

Registration and coffee

8.50am

Opening remarks

Dr Brian Tempest

Dr Brian Tempest advises Companies, Banks, Investment Funds, Private Equity & High Net Worth Individuals on their Strategy in Asia based on his wide experience in China, Japan, South East Asia and India where he has lived for the last decade. Brian...

more..

› Dr Brian Tempest, Chairman, Hale & Tempest

BIOSIMILARS

9am

Market and sales review of biosimilars in Europe

Michael Kotsanis

Michael Kotsanis has over 20 years of experience in the pharmaceutical industry and has significant senior leadership experience across the global pharmaceutical markets. He is the Chief Commercial Officer for Synthon, a position he has held since...

more..

• Biosimilars are the fastest growing market segment in the long term for generics • Performance of biosimilars in Europe to date • Prospects for biosimilars in Europe in the future • Barriers and opportunities for market adoption in the future

› Michael Kotsanis, Chief Commerical Officer, Synthon

9.30am

Operational realities of building a biosimilar and biobetter development strategy

Dr Klaus Martin at World Generic Medicines Congress Europe 2012

• Strategies to enter the lucrative field • Polpharma’s biosimilar development approaches

› Dr Klaus Martin, Head Biologics, Polpharma

10am

Commercial challenges with launching biosimilars

Peter Stenico at World Generic Medicines Congress Europe 2012

• The competitive landscape • Market factors influencing uptake of biosimilars • Implications for biosimilars

› Peter Stenico, Head Commercial Operations, Western Europe, Sandoz

10.30am

Morning Refreshments

BIG PHARMA AND GENERICS

11am

Pfizer's commitment to provide quality sterile injectables essential to the health and well-being of patients

Gregor Siebert

Gregor Siebert is Vice President Hospital Europe and Emerging Markets, EPBU. The unit is responsible for maximizing value creation in the worldwide hospital and sterile injectables market for Pfizer. Gregor’s responsibilities include the...

more..

• Characteristics of the hospital business in Europe and Emerging Markets • Pfizer’s strategy in the hospital market • The importance of quality and supply reliability in the Sterile Injectables business

› Gregor Siebert, Vice President Hospital Europe, Established Products Business, Pfizer

PRODUCT DIFFERENTIATION AND FOCUS

11.30am

Building scale, market share and value through differentiation

Rahul Garella

Rahul Garella is an experienced pharmaceutical executive with more than fifteen years of experience in the pharmaceutical business across the segments of Active pharmaceutical ingredients (APIs) and generic formulations. He currently heads up the...

more..

• How the European markets have changed in the last few years and the implications this has for generic players • Why building scale is not just about products • Commercial innovation as the bedfellow of product innovation • The Glenmark model to building value

› Rahul Garella, Senior Vice President - EU Business, Glenmark Generics

12pm

Drug Repositioning and Risk profiling as a strategy tool for generics companies

Dr. Andreas Persidis

Andreas received his Doctorate in Artificial Intelligence (AI) from Strathclyde University in the UK. In the twenty-five years since graduating, Andreas has built technology development teams at EU corporations in the engineering, software and...

more..

- the emerging healthcare market and strategy options to date
- competition issues and success drivers in this emerging market
- drug repositioning and its relevance to the generics companies
- Biovista capabilities and its role as a strategic partner of generics companies

› Dr. Andreas Persidis, CEO, Biovista Inc

12.30pm

Lunch

1.30pm

Review of launching, marketing and selling generic respiratory products

George Kapitsakis

Work Experience Jun 2011 to Present Group Product Manager in Respiratory Department in ELPEN Pharmaceutical Co. Inc. Jul 2009 - Jun 2011 Senior Product Manager in Respiratory Department in ELPEN Pharmaceutical Co. Inc. Jan 2007 – Jul 2009 Product...

more..

• Pre-launching activities • Marketing strategy vs originator • Major messages • Launching activities

› George Kapitsakis, Group product Manager, Respiratory Products, Elpen Pharmaceutical Co.

INTERNATIONAL MARKET FOCUS

2pm

Panel session: Cost Containment, Generics Prescribing and Challenges

Dr Ullrich Hanstein at World Generic Medicines Congress Europe 2012

Ashish Menocha

Accomplished Pharmaceutical Professional with more than fifteen years of Global Pharmaceutical Marketing and Management experience. Proficient in all areas relating to Pharmaceutical business with a successful performance record throughout. First...

more..

2.30pm

The API manufacturing in CEE and the market dynamics

Theodore Iliopoulos

Graduated from the University of Athens as a Chemist and has an impressive thirty seven-year career in Pharmaceutical Operations, first working for 13 years for Greek national companies before joining Bristol Myers Squibb in 1986 in a key Quality...

more..

• Overcapacity and outsourcing opportunities constraints • Growing competition posed by low-cost manufacturers in Asia • Regulatory changes that have and are expected to influence the industry • New Technologies as a global trend • IP and legal landscape • Partnerships as a critical global trend

› Theodore Iliopoulos, Vice President Operations, Polpharma

3pm

Afternoon Refreshments

3.30pm

Review of market dynamics in Japan

Yoshifumi Togo

Mr. Togo is the Deputy General Manager, Management Planning Development Department of Towa Pharmaceutical Co., Ltd. He started his business career in Yoshitomi Pharmaceutical (Existing Mitsubishi Tanabe Pharma Corporation) as a medicinal chemist...

more..

• Government promotion of generic medicines and trends of generic penetration • Challenges & opportunities for generic players • Future of Japanese generic market

› Yoshifumi Togo, Deputy General Manager, Management Planning Development Department, Towa Pharmaceutical Co., Ltd.

4pm

Opportunities and challenges for generic industry: overview of changing paradigm especially in emerging markets such as China

Jack Aurora

Dr. Jack Aurora is Ph.D. in pharmaceutical sciences with over 19 years of Quality and Compliance driven research and management experience to his credit. Dr. Aurora’s research experience is in all the dosage forms including but not limiting to...

more..

• What do the emerging markets offer and how to make the most of it? • Is it fare to believe that a single strategy is sufficient for fragmented nature of the emerging markets? • At the end, what is to be focused to survive and sustain the business, do we see a crystal ball somewhere?